Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182675 · ClinicalTrials.gov registry record · Phase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01182675 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 7 participants.
The verdict
NCT01182675, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune reconstitution. Rather than classic chemotherapeutic agents, the investigators will utilize a targeted stem cell mobilizer, plerixafor, in combination with alemtuzumab, a monoclonal antibody. Correlative scientific questions will include: 1) efficacy and characteristics of host stem cell mobilization; and 2) alemtuzumab pharmacokinetics in very young children.
Interventions
- DRUG Transplant Conditioning with Mobilization Only
- DRUG Transplant Conditioning with Mobilization and Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01182675
The ClinicalTrials.gov registry entry for NCT01182675 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transplant Conditioning with Mobilization Only is the first listed.
NCT01182675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01182675 about?
NCT01182675 is a clinical study titled "Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim". The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune reconstitution. Rather tha...
What is the current status of trial NCT01182675?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01182675?
The interventions under investigation include: Transplant Conditioning with Mobilization Only (DRUG), Transplant Conditioning with Mobilization and Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT01182675?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.